Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

NCT00910728 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis (PMF)
Post-Polycythaemia Vera
Essential Thrombocythaemia Myelofibrosis

Interventions

DRUG: AZD1480

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]
[object Object]